Lymphoma & CLL Subtypes

Loncastuximab tesirine granted orphan drug designation in the European Union for the treatment of patients with DLBCL

On September 13, 2021, the European Commission (EC) granted orphan drug...

Safety and efficacy of oral azacitidine (CC-486) plus R-CHOP in patients with previously untreated intermediate- to high-risk DLBCL: A phase I study

The combination of rituximab and cyclophosphamide,...

Zanubrutinib granted accelerated approval by the FDA for the treatment of patients with R/R MZL

On September 15, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to...

FDA approval of zanubrutinib for adult patients with Waldenström’s macroglobulinemia

On September 1, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of...

Clinical practice guidelines for transplant and cellular therapies in mantle cell lymphoma: recommendations from ASTCT, CIBMTR, and EBMT

Mantle cell lymphoma (MCL) is a B-cell lymphoma with marked...

Expression pattern and role of circular RNAs in the prognosis of mantle cell lymphoma in younger patients

Treatment with cytarabine-containing chemo-immunotherapy followed by autologous stem cell...

What is the most promising new targetable pathway in CLL?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Alexey Danilov, City of Hope...

What predicts disease progression on venetoclax?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer...